|
|
Volumn 9, Issue , 2003, Pages 285-302
|
|
The state of biopharmaceutical manufacturing
|
|
Author keywords
Bacterial cell culture; Biotechnology; E. coli; Mammalian cell culture; Protein manufacturing; Transgenics
|
|
Indexed keywords
ABCIXIMAB;
AGALSIDASE BETA;
ALEMTUZUMAB;
ALTEPLASE;
BASILIXIMAB;
BETA1A INTERFERON;
BLOOD CLOTTING FACTOR 8;
CETUXIMAB;
CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;
DACLIZUMAB;
DORNASE ALFA;
DROTRECOGIN;
ETANERCEPT;
GEMTUZUMAB OZOGAMICIN;
IBRITUMOMAB TIUXETAN;
IMIGLUCERASE;
INFLIXIMAB;
MONOCLONAL ANTIBODY CD3;
NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;
PALIVIZUMAB;
RECOMBINANT BLOOD CLOTTING FACTOR 8;
RECOMBINANT BLOOD CLOTTING FACTOR 9;
RECOMBINANT ERYTHROPOIETIN;
RITUXIMAB;
TENECTEPLASE;
TOSITUMOMAB I 131;
TRASTUZUMAB;
RECOMBINANT PROTEIN;
BACTERIAL CELL;
BACTERIUM CULTURE;
BIOTECHNOLOGY;
CELL CULTURE;
DRUG COST;
DRUG INDUSTRY;
DRUG MANUFACTURE;
FERMENTATION OPTIMIZATION;
FOOD AND DRUG ADMINISTRATION;
MAMMAL CELL;
MARKETING;
PROTEIN ANALYSIS;
PROTEIN EXPRESSION;
PROTEIN ISOLATION;
PROTEIN PURIFICATION;
PROTEIN SYNTHESIS;
REVIEW;
TRANSGENIC ORGANISM;
BIOMEDICAL TECHNOLOGY ASSESSMENT;
BIOREACTOR;
BIOSYNTHESIS;
COMMERCIAL PHENOMENA;
CULTURE TECHNIQUE;
ECONOMICS;
METHODOLOGY;
ORGANIZATION AND MANAGEMENT;
PHARMACEUTICS;
PROTEIN ENGINEERING;
UNITED STATES;
MAMMALIA;
BIOPHARMACEUTICS;
BIOREACTORS;
BIOTECHNOLOGY;
CELL CULTURE TECHNIQUES;
COMMERCE;
DRUG INDUSTRY;
PROTEIN ENGINEERING;
RECOMBINANT PROTEINS;
TECHNOLOGY ASSESSMENT, BIOMEDICAL;
UNITED STATES;
|
|
EID: 1542650080
PISSN: 13872656
EISSN: None
Source Type: Book Series
DOI: 10.1016/S1387-2656(03)09008-2 Document Type: Review |
|
Times cited : (28)
|
|
References (0)
|
